Characteristics of the patient population
| . | Secondary AML . | M1 . | M2 . | M3 . | M4 . | M5 . | M6 . | M7 . | Unclassified . | Total . |
|---|---|---|---|---|---|---|---|---|---|---|
| Total No. | 15 | 11 | 10 | 1 | 9 | 6 | 1 | 3 | 5 | 61 |
| Gender (M/F) | 12/3 | 7/4 | 6/4 | 1/0 | 3/6 | 6/0 | 1/0 | 1/2 | 4/1 | 40/21 |
| Age | ||||||||||
| Younger than 2 y | 1 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 1 | 4 |
| 2-19 y | 1 | 3 | 0 | 1 | 1 | 1 | 0 | 1 | 0 | 8 |
| 20-49 y | 4 | 4 | 4 | 0 | 4 | 1 | 0 | 2 | 2 | 21 |
| Older than 49 y | 9 | 4 | 6 | 0 | 4 | 2 | 1 | 0 | 2 | 28 |
| Source of cell sample*,† | ||||||||||
| Bone marrow | 15‡ | 9 | 10 | 0 | 7 | 5‡ | 1 | 2 | 5‡ | 54‡ |
| Peripheral blood | 0 | 21-153 | 0 | 1 | 21-153 | 1 | 0 | 1 | 0 | 71-153 |
| Status of disease | ||||||||||
| Untreated | 5 | 51-153 | 4 | 1 | 6 | 1 | 0 | 2 | 1 | 251-153 |
| Remission | 6‡ | 3 | 3 | 0 | 0 | 3 | 1 | 0 | 2‡ | 18‡ |
| Relapsed/resistant | 4‡ | 3 | 3 | 0 | 31-153 | 2‡ | 0 | 1 | 2‡ | 181-153 |
| Prognostic implication of karyotype1-155 | ||||||||||
| Favorable | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Intermediate | 1 | 2 | 3 | 0 | 3 | 2 | 0 | 0 | 0 | 11 |
| Unfavorable | 14 | 9 | 7 | 0 | 6 | 4 | 1 | 2 | 5 | 48 |
| . | Secondary AML . | M1 . | M2 . | M3 . | M4 . | M5 . | M6 . | M7 . | Unclassified . | Total . |
|---|---|---|---|---|---|---|---|---|---|---|
| Total No. | 15 | 11 | 10 | 1 | 9 | 6 | 1 | 3 | 5 | 61 |
| Gender (M/F) | 12/3 | 7/4 | 6/4 | 1/0 | 3/6 | 6/0 | 1/0 | 1/2 | 4/1 | 40/21 |
| Age | ||||||||||
| Younger than 2 y | 1 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 1 | 4 |
| 2-19 y | 1 | 3 | 0 | 1 | 1 | 1 | 0 | 1 | 0 | 8 |
| 20-49 y | 4 | 4 | 4 | 0 | 4 | 1 | 0 | 2 | 2 | 21 |
| Older than 49 y | 9 | 4 | 6 | 0 | 4 | 2 | 1 | 0 | 2 | 28 |
| Source of cell sample*,† | ||||||||||
| Bone marrow | 15‡ | 9 | 10 | 0 | 7 | 5‡ | 1 | 2 | 5‡ | 54‡ |
| Peripheral blood | 0 | 21-153 | 0 | 1 | 21-153 | 1 | 0 | 1 | 0 | 71-153 |
| Status of disease | ||||||||||
| Untreated | 5 | 51-153 | 4 | 1 | 6 | 1 | 0 | 2 | 1 | 251-153 |
| Remission | 6‡ | 3 | 3 | 0 | 0 | 3 | 1 | 0 | 2‡ | 18‡ |
| Relapsed/resistant | 4‡ | 3 | 3 | 0 | 31-153 | 2‡ | 0 | 1 | 2‡ | 181-153 |
| Prognostic implication of karyotype1-155 | ||||||||||
| Favorable | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Intermediate | 1 | 2 | 3 | 0 | 3 | 2 | 0 | 0 | 0 | 11 |
| Unfavorable | 14 | 9 | 7 | 0 | 6 | 4 | 1 | 2 | 5 | 48 |
The prognostic implication of the karyotype was classified according to Grimwade et al.17 The cases of acute myeloid leukemia (AML) that arose from pre-existing myelodysplasia are referred to as secondary AML.
Two 2 bone marrow samples were analyzed in 7 patients: 4 patients with secondary AML, 1 patient with AML M5, and 2 of the unclassified cases. In terms of disease status, the second samples were taken from 3 patients in complete hemotological remission and 4 patients with resistant or relapsed disease.
Both bone marrow and peripheral blood samples were available for 3 patients.
Includes patient or patients for whom 2 bone marrow samples were analyzed.
Includes patient or patients for whom both bone marrow and peripheral blood samples were available.
Cytogenetic findings were not available for one patient.